Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
<p>Background: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) ch...
主要な著者: | Landray, M, Haynes, R, Hopewell, J, Parish, S, Aung, T, Tomson, J, Wallendszus, K, Craig, M, Jiang, L, Collins, R |
---|---|
フォーマット: | Journal article |
出版事項: |
Massachusetts Medical Society
2014
|
類似資料
-
Effects of extended-release niacin with laropiprant in high-risk patients.
著者:: Landray, M, 等
出版事項: (2014) -
Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
著者:: Haynes, R, 等
出版事項: (2019) -
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
著者:: HPS2-THRIVE Collaborative Group, 等
出版事項: (2013) -
The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
著者:: Kent, S, 等
出版事項: (2016) -
Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
著者:: Parish, S, 等
出版事項: (2018)